Right now, about 12% of American aged 18 or older (or 1 in 8 adults) are taking GLP-1 — glucagon-like peptide-1 — receptor ...

Addiction and obesity share deep neurological roots. Can new treatments like GLP-1 drugs and MEAI help break the cycle?

Just ask Tom Brady—arguably the greatest quarterback of all time. He doesn’t have the sculpted physique of a bodybuilder, yet ...

Global Partners LP (NYSE:GLP) reported a revenue of $4.19 billion in Q4 of 2024, missing estimates by $1.62 billion. EPS was ...

Student scientists have developed an incredible new way to synthesize drugs on plants — and they're using Ozempic as their ...

For years, people taking GLP-1 type drugs (e.g., Ozempic, Wegovy) have noticed that the medicines didn’t just help them to ...

"It's called GLP-1 receptor," said Dr. Atul Malhotra from the UC San Diego School of Medicine. It’s already FDA-approved to ...

In this week’s edition of InnovationRx, we look at the policy uncertainty around vaccines, sex differences in GLP-1 drug side ...

Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Viking Therapeutics ( VKTX -0.30%) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may ...